Antibodies to brain antigens are present in stroke survivors. In this study, we assessed autoantibody responses to white matter antigens, their correlation to white matter disease and stroke outcome. Antibody titers (immunoglobulin G [igG]) to myelin basic protein (MBP), proteolipid protein (PLP) and tetanus toxoid (TT) were available at one or more time points for 112 subjects with ischemic stroke. In comparison to the control subjects (N = 40), there was a global decrease in IgG titers to TT early after stroke. Patients with white matter disease on magnetic resonance imaging had elevated titers of antibodies to both MBP and PLP at 30 days after stroke, and anti-MBP antibodies were associated with worse outcome. The potential pathologic consequences of antibodies to white matter, especially MBP, is deserving of further investigation.
Introduction
The presence of autoimmune responses to central nervous system (CNS) antigens in patients with stroke has been appreciated since the early 1970s. In fact, early studies showed that the T cell response to myelin associated proteins was more robust in stroke survivors than in patients with multiple sclerosis (Youngchaiyud et al., 1974; Kallen et al., 1977) . We recently showed that TH1 type cellular immune responses to brain antigens occur following stroke and the likelihood such responses is enhanced by the occurrence of systemic infection (Becker et al., 2011) . Further, we found that the TH1 response to myelin basic protein (MBP) was an independent predictor of stroke outcome -more robust cellular responses to MBP were associated with a decreased likelihood of good outcome at 90 days after stroke onset.
Recent studies have identified antibodies to neurofilament and portions of the N-methyl-D-aspartate (NMDA) receptor in patients with stroke (Bornstein et al., 2001; Dambinova et al., 2003) . The relevance of these autoantibodies to stroke outcome is unknown. Using the same cohort of patients with ischemic stroke in which we assessed the cellular immune response to brain antigens, we now characterize the humoral immune response to brain antigens by measuring the titers of antibodies to MBP and proteolipid protein (PLP).
Materials and methods

Research subjects
We prospectively enrolled patients with ischemic stroke admitted to Harborview Medical Center from 9/2005 to 5/2009 who were at least 18 years of age, could be enrolled within 72 h of symptom onset and were felt not likely to die from their stroke. Patients with ongoing therapy for malignancy, known history of HIV, Hepatitis B or C, history of brain tumor, anemia (hematocrit b 35 on admission), and those taking immunomodulatory drugs were excluded. Blood was drawn as soon as possible after stroke onset and at 3, 7, 30, 90, 180 and 365 days after stroke onset. Plasma and serum were frozen at − 80°until use. The study was approved by the Institutional Review Board and all patients or their surrogates provided informed consent.
Clinical and infection data
Demographic and clinical data were collected on all patients. Stroke severity was determined by the National Institutes of Health Stroke Scale (NIHSS) score and outcome by the stroke impact scale (SIS) (Duncan et al., 2003) . In hospital infection was defined as clinical symptoms of an infection (fever and/or pyuria for urinary tract infection [UTI] and fever and/or productive cough and radiographic evidence of consolidation for pneumonia [PNA] ) and positive culture data (for both PNA and UTI). Total infarct volume on initial diffusion weighted MRI imaging was calculated by the ABC/2 method (Sims Journal of Neuroimmunology 252 (2012) 106-112 
